Notably, among 86 serous ovarian cancer cases, MAP7 expression was predominantly higher in high-grade tumors, highlighting its potential role in the progression and aggressiveness of ovarian cancer. The gene discussed is MAP7; the disease is ovarian serous adenocarcinoma.